Wednesday, 18 Sep 2019

You are here

Are Non-TNF Biologics Superior to TNF inhibitors?

Current ACR and EULAR guidelines list TNF-inhibitors (TNFi) abatacept, rituximab, and tocilizumab as being equally effective after methotrexate or as second line therapies when treating rheumatoid arthritis. An analysis from the Swedish Rheumatology Register shows that the non-TNFi biologic DMARDs (bDMARDs), in particular tocilizumab and rituximab, are more effective than TNFi. 

RA patients in this registry were included if they initiated TNFi, rituximab, abatacept or tocilizumab between 2010–2016 as first bDMARD (n = 9333), or after switch from TNFi as first bDMARD (n = 3941).

Effectiveness was assessed 3 and 12 months based on the proportion remaining on therapy and with EULAR Good Response, HAQ improvement >0.2, zero swollen/tender joints and CDAI remission.

At 1 year, patients starting non-TNFi (vs TNFi) as first bDMARD had a higher proportion remaining on drug and reaching most response outcomes as first bDMARD (EULAR Good Response/HAQ improvement):

  • TNFi 24.9/25.4%
  • Rituximab 28.6/37.2%
  • Abatacept 31.9/33.7%
  • Tocilizumab 50.9/43.1%).

After switch from a first TNFi, rituximab and tocilizumab, but not abatacept, were associated with significantly better response measures than continuing TNFi (1-year EULAR Good Response/HAQ improvement):

  • TNFi 11.6/16.1%
  • Rituximab 24.8/33.2%
  • Abatacept 13.1/17.5%
  • Tocilizumab 34.1/29.4%)

While guidelines are based on metanalyses and expert consensus (and not head-to-head trials), these real world data suggest high efficacy when using non-TNFi bDMARDs, in particular tocilizumab and rituximab, as either the first bDMARD or as a switch candidate after TNFi.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Anakinra Shows Benefits in Cytokine Storm

The interleukin (IL)-1 receptor antagonist anakinra (Kineret) showed promise in critically ill children who develop the often-lethal condition known as secondary hemophagocytic lymphohistiocytosis (sHLH)/macrophage activation syndrome (MAS), a retrospective single-center study found.

 

Prior Authorizations Delay Care in Rheumatology

Physicians who believe their patients' health is negatively affected by insurers' demands for prior authorization, and the delays that often result, will find that opinion vindicated by a new study of rheumatology care: when permission had to be sought from insurers to provide intravenous drugs, average time to begin treatment was longer and patients had twice the corticosteroid exposure, a single-center analysis found.

Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis

The US Food and Drug Administration (FDA) on Friday, August 16, approved AbbVie JAK1 inhibitor, Rinvoq (upadacitinib) for adults with  rheumatoid arthritis with moderately to severely active disease either not responding to, or intolerant of, methotrexate (MTX). 

FINCH2: Filgotinib in Biologic Refractory Rheumatoid Arthritis

The FINCH2 study has shown that filgotinib, an oral once daily JAK 1 inhibitor, is highly effective in rheumatoid arthritis (RA) patients who failed to respond to prior biologic therapy.

Rituximab Safety Concerns when Used in anti-TNF Refractory RA

The SUNSTONE study evaluated the long‐term safety of rituximab in rheumatoid arthritis (RA) previously exposed to ≥1 anti–tumor necrosis factor inhibitors (TNFi) and showed a stable, but high, rate of serious infections, opportunistic infections and an overall higher mortality rate.